SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society